이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Sartorius Stedim Biotech 과거 수익 실적

과거 기준 확인 1/6

Sartorius Stedim Biotech은 연평균 17%의 비율로 수입이 증가해 온 반면, Life Sciences 산업은 수입이 증가했으며, 연간 19.6%였습니다. 매출은 연평균 18.5%의 비율로 증가했습니다. Sartorius Stedim Biotech의 자기자본이익률은 6.7%이고 순이익률은 9.4%입니다.

주요 정보

17.0%

수익 성장률

16.9%

EPS 성장률

Life Sciences 산업 성장	36.9%
매출 성장률	18.5%
자기자본 수익률	6.7%
순이익	9.4%
다음 실적 업데이트	19 Jul 2024

최근 과거 실적 업데이트

Recent updates

수익 및 비용 분석

Sartorius Stedim Biotech 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

BATS-CHIXE:DIMP 수익, 비용 및 수입 (EUR Millions )
날짜	수익	수익	G+A 비용	R&D 비용
31 Mar 24	2,716	255	625	129
31 Dec 23	2,776	310	618	130
30 Sep 23	2,959	460	598	131
30 Jun 23	3,170	635	603	132
31 Mar 23	3,356	717	604	135
31 Dec 22	3,493	876	612	132
30 Sep 22	3,381	681	605	125
30 Jun 22	3,259	625	577	123
31 Mar 22	3,094	559	564	119
31 Dec 21	2,887	414	532	111
30 Sep 21	2,639	523	479	103
30 Jun 21	2,393	469	450	98
31 Mar 21	2,143	398	417	89
31 Dec 20	1,910	336	392	84
30 Sep 20	1,743	299	373	84
30 Jun 20	1,600	255	353	81
31 Mar 20	1,520	254	334	81
31 Dec 19	1,441	235	318	79
30 Sep 19	1,393	247	308	68
30 Jun 19	1,336	238	301	65
31 Mar 19	1,274	223	293	61
31 Dec 18	1,212	208	283	61
30 Sep 18	1,172	185	277	60
30 Jun 18	1,121	173	264	59
31 Mar 18	1,093	162	259	57
31 Dec 17	1,081	161	258	53
30 Sep 17	1,073	151	252	53
30 Jun 17	1,089	157	255	50
31 Mar 17	1,075	157	250	49
31 Dec 16	1,052	154	244	48
30 Sep 16	1,009	145	242	47
30 Jun 16	971	142	234	46
31 Mar 16	926	136	226	43
31 Dec 15	884	118	217	42
30 Sep 15	850	111	207	43
30 Jun 15	781	89	197	35
31 Mar 15	734	76	189	39
31 Dec 14	684	72	184	34
30 Sep 14	646	71	173	39
30 Jun 14	620	67	168	39
31 Mar 14	604	68	165	38
31 Dec 13	588	66	159	36
30 Sep 13	567	63	151	34

양질의 수익: DIMP 에는 €59.6M 큰 일회성 득실이 있습니다. €59.6M 은 지난 12개월 간의 재무 결과에 31st March, 2024 까지 영향을 미쳤습니다.

이익 마진 증가: DIMP 의 현재 순이익 이익률 (9.4%) 작년보다 낮습니다 (21.4%).

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: DIMP 의 수입은 지난 5년 동안 매년 17% 씩 증가했습니다.

성장 가속화: DIMP 은(는) 지난 1년 동안 마이너스 수익 성장을 기록했기 때문에 5년 평균과 비교할 수 없습니다.

수익 대 산업: DIMP 은 지난 1년 동안 마이너스 수익 성장( -64.5% )을 기록하여 Life Sciences 업계 평균( -1.7% ).

Sartorius Stedim Biotech 과거 수익 실적

과거 기준 확인 1/6

주요 정보

최근 과거 실적 업데이트

Sartorius Stedim Biotech S.A. to Report Nine Months, 2024 Results on Oct 17, 2024

Third quarter 2023 earnings released: EPS: €0.28 (vs €2.22 in 3Q 2022)

Second quarter 2023 earnings released: EPS: €1.44 (vs €2.33 in 2Q 2022)

Full year 2022 earnings released: EPS: €9.51 (vs €4.50 in FY 2021)

Sartorius Stedim Biotech S.A. to Report Fiscal Year 2022 Results on Jan 26, 2023

Third quarter 2022 earnings released: EPS: €2.22 (vs €1.60 in 3Q 2021)

Recent updates

Insufficient new directors

Investor sentiment deteriorates as stock falls 27%

Insufficient new directors

Upcoming dividend of €0.69 per share

New minor risk - Profit margin trend

Dividend of €0.69 announced

Insufficient new directors

Sartorius Stedim Biotech S.A. has filed a Follow-on Equity Offering in the amount of €1.2 billion.

Sartorius Stedim Biotech S.A. has completed a Follow-on Equity Offering in the amount of €1.2 billion.

Insufficient new directors

Sartorius Stedim Biotech S.A. to Report Nine Months, 2024 Results on Oct 17, 2024

Investor sentiment improves as stock rises 16%

Insufficient new directors

Third quarter 2023 earnings released: EPS: €0.28 (vs €2.22 in 3Q 2022)

Investor sentiment deteriorates as stock falls 16%

Less than half of directors are independent

Second quarter 2023 earnings released: EPS: €1.44 (vs €2.33 in 2Q 2022)

Less than half of directors are independent

Investor sentiment deteriorates as stock falls 15%

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Full year 2022 earnings released: EPS: €9.51 (vs €4.50 in FY 2021)

Sartorius Stedim Biotech S.A. Provides Earnings Guidance for the Fiscal Year 2023

Less than half of directors are independent

Sartorius Stedim Biotech S.A. to Report Fiscal Year 2022 Results on Jan 26, 2023

Sartorius Stedim Biotech S.A., Annual General Meeting, Mar 27, 2023

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: €2.22 (vs €1.60 in 3Q 2021)

Sartorius Stedim Biotech S.A. Provides Earnings Guidance for the Fiscal Year 2022

Sartorius Stedim Biotech S.A. (ENXTPA:DIM) entered into a definitive agreement to acquire Albumedix Ltd. from private investors for approximately £420 million.

Second quarter 2022 earnings released: EPS: €2.33 (vs €1.61 in 2Q 2021)

Less than half of directors are independent

First quarter 2022 earnings released: EPS: €2.93 (vs €1.24 in 1Q 2021)

Sartorius Stedim Biotech S.A. Confirms Earnings Guidance for the Year 2022

Sartorius Stedim Biotech S.A. Approves Dividend for the Fiscal Year 2021

Upcoming dividend of €1.26 per share

Less than half of directors are independent

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Sartorius Stedim Biotech S.A. Updates Earnings Guidance for the Year 2022

Sartorius Stedim Biotech S.A. Recommends Dividend

Sartorius Stedim Biotech S.A. (ENXTPA:DIM) completed the acquisition of chromatography equipment division from Novasep Holding SAS.

Sartorius Stedim Biotech Provides Earnings Guidance for the Full Year 2022

Third quarter 2021 earnings released: EPS €1.60 (vs €1.10 in 3Q 2020)

Second quarter 2021 earnings released: EPS €1.56 (vs €0.73 in 2Q 2020)

Sartorius Stedim Biotech S.A. Raises Forecast for the Full Year 2021

First quarter 2021 earnings released: EPS €1.24 (vs €0.81 in 1Q 2020)

Sartorius Stedim Biotech Raises Consolidated Sales Guidance for 2021

Sartorius Stedim Biotech Increases Earnings Guidance for 2021

Full year 2020 earnings released: EPS €3.88 (vs €2.54 in FY 2019)

Revenue misses expectations

New 90-day high: €362

Sartorius Stedim Biotech S.A. to Report Nine Months, 2021 Results on Oct 20, 2021

Sartorius Stedim Biotech S.A. (ENXTPA:DIM) signed an agreement to acquire chromatography equipment division from Novasep Holding SAS.

Sartorius Stedim Biotech S.A. (ENXTPA:DIM) completed the acquisition of BIA Separations d.o.o.

Sartorius Stedim Biotech S.A. to Report Q1, 2021 Results on Apr 21, 2021

Sartorius Stedim Biotech S.A. (ENXTPA:DIM) entered into a definitive agreement to acquire BIA Separations d.o.o. for ?€360 million.

Sartorius Aktiengesellschaft (XTRA:SRT) and Sartorius Stedim Biotech S.A. (ENXTPA:DIM) completed the acquisition of certain businesses from Danaher Corporation (NYSE:DHR).

수익 및 비용 분석

수익 및 매출 내역

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

자기자본 수익률

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기